Study of BI 3000202 in people with and without liver problems
This study tests how a new medicine, BI 3000202, is absorbed into the blood. It includes people with different levels of liver function (normal, mild, moderate, or severe) to see if liver problems affect how the medicine works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- Your body mass index (BMI) is between 18.5 and 42.0.
- If you have liver problems, they must be stable (no major changes or new treatments in the last 3 months).
- You do not have active or untreated tuberculosis (TB).
- You have not had a live vaccine within the last 8 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests how a new medicine, BI 1291583, enters the blood in people who have different levels of liver function (from normal to mild, moderate, or severe liver problems). It helps doctors understand if the dose needs to be adjusted for liver health.
This study tests how well different doses of a new drug (BI 3804379) are tolerated. It is for healthy people and for patients with MASH (a type of fatty liver disease) who have advanced liver scarring.
This trial tests how safe and tolerable different doses of the study drug BI 3814916 are in healthy adults. It helps find the right dose for future studies.
This trial tests how a new medicine, LY3537031, moves through the body and how safe it is for people with different levels of liver function. It includes people with normal livers and those with mild, moderate, or severe liver impairment.
This study in healthy volunteers looks at how much of the drug BI 3034701 enters the bloodstream when given in two different ways. It helps find the best way to deliver the drug for future studies.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
Hear when a new Hepatic Impairment trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.